Technical Analysis for PLX - Protalix BioTherapeutics, Inc.

Grade Last Price % Change Price Change
grade B 3.59 -0.55% -0.02
PLX closed down 0.55 percent on Friday, June 5, 2020, on 81 percent of normal volume. Note that the stock is in overbought territory based on its Slow Stochastic indicator (14, 3, 3) -- sideways movement or a pullback should not be unexpected.

Trend Table & Recent Signals

ADX Long Term Intermediate Term Short Term
Weak or Absent Up Up Up
Historical PLX trend table...

Date Alert Name Type % Chg
Overbought Stochastic Strength 0.00%
Pocket Pivot Bullish Swing Setup -0.55%
Stochastic Reached Overbought Strength -0.55%
Overbought Stochastic Strength -0.55%
NR7 Range Contraction 4.36%
Inside Day Range Contraction 4.36%
Earnings Movers Other 4.66%
Pocket Pivot Bullish Swing Setup 4.36%
Spinning Top Other 4.36%
Earnings Movers Other 4.36%

Get a Trading Assistant

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:


Protalix BioTherapeutics, Inc., a biopharmaceutical company, together with its subsidiary, Protalix Ltd., focuses on the development and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx protein expression system. It offers taliglucerase alfa for injection, which is marketed under the ELELYSO brand name, as an enzyme replacement therapy for the long-term treatment of adult patients with a confirmed diagnosis of type 1 Gaucher disease. The company's product pipeline includes PRX-102, a therapeutic protein candidate for the treatment of Fabry disease; PRX-105, a plant cell expressed pegylated recombinant acetylcholinesterase product candidate for biodefense and other indications; and an orally-administered glucocerebrosidase enzyme for the treatment of Gaucher patients utilizing oral delivery of the recombinant enzyme produced within carrot cells. Its product pipeline also comprises PRX-106 or pr-antiTNF, a plant cell expressed recombinant fusion protein made from the soluble form of the human TNF receptor and an antibody portion, which is being developed as a treatment of certain immune diseases, such as rheumatoid arthritis, Chrohn's disease, placque psoriasis, and other autoimmune disorders; and two additional undisclosed therapeutic proteins that are being evaluated in animal studies. It has a collaboration and licensing agreement with Teva Pharmaceutical Industries Ltd. to develop and manufacture two proteins using its ProCellEx protein expression system. The company was founded in 1993 and is based in Carmiel, Israel.
Biotechnology Biopharmaceutical Life Sciences Biology Rheumatoid Arthritis Autoimmune Disorders Enzyme Replacement Therapy Fabry Disease Gaucher Disease Recombinant Dna Treatment Of Fabry Disease

Is PLX a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength


Indicator Value
52 Week High 4.865
52 Week Low 1.7
Average Volume 229,088
200-Day Moving Average 2.87
50-Day Moving Average 3.19
20-Day Moving Average 3.25
10-Day Moving Average 3.41
Average True Range 0.27
ADX 17.88
+DI 28.85
-DI 17.22
Chandelier Exit (Long, 3 ATRs ) 2.90
Chandelier Exit (Short, 3 ATRs ) 3.61
Upper Bollinger Band 3.71
Lower Bollinger Band 2.78
Percent B (%b) 0.87
BandWidth 28.53
MACD Line 0.08
MACD Signal Line 0.03
MACD Histogram 0.0457
Fundamentals Value
Market Cap 478.75 Million
Num Shares 133 Million
EPS -0.60
Price-to-Earnings (P/E) Ratio -5.99
Price-to-Sales 6.07
Price-to-Book 0.00
PEG Ratio -0.16
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 3.88
Resistance 3 (R3) 3.88 3.79 3.83
Resistance 2 (R2) 3.79 3.72 3.79 3.81
Resistance 1 (R1) 3.69 3.67 3.65 3.69 3.80
Pivot Point 3.60 3.60 3.58 3.60 3.60
Support 1 (S1) 3.50 3.53 3.46 3.50 3.38
Support 2 (S2) 3.41 3.48 3.41 3.37
Support 3 (S3) 3.31 3.41 3.35
Support 4 (S4) 3.31